Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.3K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.3K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

646
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
646
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

612
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
612
Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

633
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
633
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

514
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
514
Inhaled Medications01:23

Inhaled Medications

605
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
605

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Th2 and Th17/Th1 Inflammatory Profiles in Chronic Rhinosinusitis: Associations with Vitamin D Status and Disease Severity.

International journal of molecular sciences·2026
Same author

Deep Learning-Assisted 3D Analysis of Coronoid Process Changes After Orthognathic Surgery.

Journal of clinical medicine·2026
Same author

Association of Perineural and Lymphovascular Invasion with Clinical and Pathological T Staging in Head and Neck Squamous Cell Carcinoma.

Journal of clinical medicine·2026
Same author

From Structure to Aesthetics: The Importance of Nasal Bone Thickness in Rhinoplasty Planning.

Journal of clinical medicine·2026
Same author

Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma: The Association with Tumor Stage and Primary Tumor Location.

Journal of clinical medicine·2026
Same author

The Use of Conical Powered Burrs in Surgery of the Bony Nasal Pyramid.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Dec 12, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.2K

Intranasal steroid therapy - EPOS 2020.

Piotr Rot1, Piotr Rapiejko1, Dariusz Jurkiewicz1

  • 1Klinika Otolaryngologii z Klinicznym Oddziałem Chirurgii Czaszkowo-Szczękowo-Twarzowej, Wojskowy Instytut Medyczny, Warszawa.

Otolaryngologia Polska = the Polish Otolaryngology
|August 8, 2020
PubMed
Summary

Intranasal glucocorticoids are key for treating rhinosinusitis and allergic rhinitis. This review examines their role in nasal sinusitis management based on EPOS 2020 guidelines, considering Polish healthcare realities.

Keywords:
EPOS 2020glucocorticoidsrhinosinusitis

More Related Videos

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.6K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.1K

Related Experiment Videos

Last Updated: Dec 12, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.2K
Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
07:04

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

10.6K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.1K

Area of Science:

  • Otolaryngology
  • Allergology
  • Pharmacology

Background:

  • Intranasal glucocorticoids (INGCs) are primary treatments for rhinosinusitis and allergic rhinitis due to their potent anti-inflammatory effects.
  • Mometasone furoate, a novel INGC, gained over-the-counter status in Poland in 2019 for allergic rhinitis, noted for its safety and efficacy.
  • Expert recommendations advocate for broader INGC applications beyond current approved indications.

Purpose of the Study:

  • To review the role of INGCs in nasal sinusitis treatment protocols.
  • To align the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) guidelines with Polish clinical practice.
  • To discuss the therapeutic positioning of INGCs in managing sinonasal conditions.

Main Methods:

  • Literature review of EPOS 2020 guidelines.
  • Analysis of current therapeutic strategies for rhinosinusitis and allergic rhinitis.
  • Consideration of country-specific factors relevant to Poland.

Main Results:

  • INGCs are recommended for a wide spectrum of rhinosinusitis and allergic rhinitis.
  • EPOS 2020 provides updated recommendations for managing these conditions.
  • The integration of INGCs into Polish treatment algorithms requires consideration of local factors.

Conclusions:

  • INGCs are essential in managing inflammatory sinonasal diseases.
  • Adherence to EPOS 2020 guidelines, adapted for Poland, can optimize patient outcomes.
  • Further evaluation of INGCs in broader indications is warranted.